Lameness horses collaboration Sleip app artificial intelligence
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
Search
PRRS vaccine celebrates 25 years in Europe
Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe
Mastitis dairy cows prevent antibiotic resistance
The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.
Embracing diversity in clinical trials
At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
U.S. FDA grants priority review for spesolimab in GPP
U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis
new_analysis_nintedanib_SSc_ILD
Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
George Okafo
My career challenge at Boehringer Ingelheim by George Okafo. Read it now!
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
TwistPak Mixing platform for swine vaccines
TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
Listen to the sounds disrupting farms worldwide
A pioneer in Precision Livestock Farming, Prof. Daniel Berckmans reveals how online monitoring technology is bringing healthier pigs closer to farmers and consumers
FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Boehringer Olaf Scholz break ground for innovation center
Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Is artificial intelligence the future of farming?
The impact of carbon reduction projects
Boehringer Ingelheim voluntarily contributes to carbon reduction projects that benefit sustainable development.
REACH / GHS / Material safety data sheets
We are continuously working on these topics with the aim to be in compliance with requirements deriving from these legislations.
COVID-19: Healthcare Professionals
Faced with COVID-19, everyone has to adjust their private and professional lives. This is especially true for healthcare professionals.
Vaccine prevent calf diarrhea
Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by bovine coronavirus
The geography of pet parasites is changing
Climate change facilitates new pet parasites way beyond ticks and flea bites in dogs and cats
Social innovation: catalyst for sustainable health solutions
Supporting social innovators drives sustainable health solutions in underserved communities. Learn more about Boehringer Ingelheim Social Engagements.
World-Psoriasis-Day-IFPA-Interview
Interview with the International Federation of Psoriasis Associations (IFPA)
Rahul Prasad
Rahul J. Prasad, Senior Consultant with Corporate Strategy & Consulting, describes his job as one that suits both of his passions: data analysis and variety.
Generalized pustular psoriasis: Unmet needs
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the impact of living with GPP including unseen challenges and future management.
1885-1948: Innovative beginnings
The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
FDA approval NexGard PLUS for dogs
Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites